DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris

Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acne Vulgaris

Intervention: Dapsone Formulation A (Drug); Dapsone Formulation B (Drug); Dapsone Formulation C (Drug); Dapsone 5% Gel (Drug)

Phase: Phase 1

Status: Withdrawn

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan

Summary

This study will assess the safety, tolerability, and efficacy of dapsone in subjects with acne vulgaris following 12 weeks of treatment.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Change from Baseline in Inflammatory Lesion Count

Secondary outcome:

Change from Baseline in Non-Inflammatory Lesion Count

Change from Baseline in Total Lesion Count

Percentage of Subjects With a Global Acne Assessment Score (GAAS) of 0 or 1

Eligibility

Minimum age: 12 Years. Maximum age: 35 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participation in Allergan study 225678-004

Exclusion Criteria:

- Anticipates the need for surgery or hospitalization during the study

Locations and Contacts

Additional Information

Starting date: March 2013
Last updated: February 22, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017